Targovax – Therapeutic cancer vaccines

Targovax is an innovation driven specialist in immuno-oncology.

Targovax ASA will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017. A presentation by Targovax's management to investors, analysts and the press will take place in Oslo at 10:00 CET.

Read more

Even in late stage cancer patients with low immunogenic tumor types, our virus-based immunotherapy can reinstate the immune system’s ability to recognize and attack cancer cells. In addition, studies with our peptide-based Immunotherapy have shown immune responses in difficult to treat RAS cancer patients.

Read more

Ringing the bell at the Oslo Axess stock exchange to announce the start of public trading of Targovax. On 8 July Targovax was listed on the Oslo Axess stock exchange. A prospectus for the listing and a complete description of all conditions for the subsequent offering can be downloaded here.

Read more
  • Targovax ASA: Fourth quarter and full year 2016 results

    February 16, 2017

    Oslo, Norway, 16 February 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results.

    A meeting for investors, analysts and press will ta (...)

    Read more
  • Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February

    February 6, 2017

    Oslo, Norway, 6 February 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017. A presentation by Targovax's management to investors,  (...)

    Read more
  • Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients

    February 2, 2017

    Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate

     Full data set from first patient cohort to be submitted for presentation at ASCO annual meeting in June

    Oslo, Norway, 2 February 2017 - Targovax AS (...)

    Read more
  • Targovax announces appointment of Erik Digman Wiklund as CFO

    January 5, 2017

    Oslo, Norway, 5 January 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that Erik Digman Wiklund has been appointed as the Company's new Chief Financial Officer, and will take up t (...)

    Read more
  • Targovax to present at DNB healthcare conference

    December 13, 2016

    Oslo, Norway, 13 December 2016: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present a corporate overview at (...)

    Read more
  • Targovax ASA: Third quarter 2016 results

    November 17, 2016

    Oslo, Norway, 17 November 2016 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces its third quarter 2016 results. A meeting for investors, analysts and pre (...)

    Read more